The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)
Crossref DOI link: https://doi.org/10.1007/s12282-017-0781-0
Published Online: 2017-05-09
Published Print: 2018-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tomioka, Nobumoto
Azuma, Manabu
Ikarashi, Mayuko
Yamamoto, Mitsugu
Sato, Masako
Watanabe, Ken-ichi
Yamashiro, Katsushige
Takahashi, Masato
License valid from 2017-05-09